| 1 Leaving the study early: 1. Any reason |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.1 short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
0.49 [0.20, 1.19] |
| 2 Global state: 1. Change over time ‐ no better or deterioration (ITT) |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 2.1 short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
0.92 [0.64, 1.31] |
| 3 Adverse events: Movement disorders |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 3.1 akathisia ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
0.66 [0.39, 1.11] |
| 3.2 dyskinesia ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
0.82 [0.33, 2.05] |
| 3.3 parkinsonism ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
1.13 [0.80, 1.60] |
| 4 Other adverse events: 1. Anticholinergic |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 4.1 blurred vision ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
1.06 [0.15, 7.24] |
| 4.2 dry mouth ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
1.32 [0.57, 3.09] |
| 5 Other adverse events: 2. Arousal |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 5.1 drowsiness ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
0.98 [0.49, 1.94] |
| 5.2 insomnia ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
0.97 [0.62, 1.52] |
| 6 Other adverse events: 3. Cardiovascular |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 6.1 angina pectoris ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
0.53 [0.17, 1.65] |
| 6.2 faintness, dizziness, weakness ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
0.85 [0.50, 1.45] |
| 6.3 palpitations ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
0.12 [0.02, 0.90] |
| 7 Other adverse events: 4. Central nervous system |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 7.1 headache ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
0.79 [0.37, 1.72] |
| 7.2 paraesthesia ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
0.53 [0.05, 5.66] |
| 8 Other adverse events: 5. Gastrointestinal |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 8.1 constipation ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
1.38 [0.66, 2.86] |
| 8.2 loss of appetite ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
0.91 [0.46, 1.77] |
| 8.3 nausea and vomiting ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
0.85 [0.36, 1.98] |
| 9 Other adverse events: 6. Skin |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 9.1 oedema |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
3.17 [0.13, 76.16] |
| 9.2 pruritus ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
0.71 [0.12, 4.05] |
| 9.3 rash ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
1.06 [0.07, 16.48] |
| 10 Other adverse events: 7. Genitourinary |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 10.1 diminished sexual desire |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 10.2 increased sexual desire ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 10.3 micturition disturbances ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
1.06 [0.15, 7.24] |
| 11 Other adverse events: 8. Others |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 11.1 sweating ‐ short term |
1 |
105 |
Risk Ratio (M‐H, Random, 95% CI) |
0.71 [0.12, 4.05] |
